0.00Open0.00Pre Close0 Volume0 Open Interest5.00Strike Price0.00Turnover625.67%IV792.86%PremiumAug 16, 2024Expiry Date0.00Intrinsic Value100Multiplier18DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type0.1951Delta0.3514Gamma11.20Leverage Ratio-0.0058Theta0.0000Rho2.19Eff Leverage0.0003Vega
Galecto Stock Discussion
NEWS
Galecto Announces First Patient Dosed in an Investigator-Initiated Phase 2 Trial of GB1211 in Combination with Pembrolizumab
Galecto, Inc. announced the enrollment of the first patient in an investigator-initiated Phase 2 trial to evaluate GB1211, a galectin-3 inhibitor, in combination with pembrolizumab for metastatic melanoma and head and neck squamous cell carcinoma. Galecto aims to explore GB1211's potential to enhance the effectiveness of pembrolizumab in various can...
@FiReBiTriXiE @jimmy the trader @MangoXXX @PYUN970IHaveChosen @Ripper @Rivera @Trytosaveabit @VinylEagle @Wind_Storm @8 Seconds
Topline Results from MYLOX-1 Trial Demonstrate Reduction in Fibrosis of the Bone Marrow in Patients with Myelofibrosis
AH volume 1.2M and growing
positive trial data 👍
2 MINUTES AGO, 4:05 PM EST
VIA GLOBENEWSWIRE
No comment yet